Description
Seeking healthy infants 5 < 8 months of age for a study to determine whether investigational mRNA vaccines can prevent respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) infection.
Overview
Participants in this study will either get one of two doses of the experimental mRNA vaccine or a placebo (looks like the vaccine but contains no medicine). The vaccines will be given as an injection three times over a period of 4 months. After the third and final injection, there will be periodic follow-up visits over 2 years. To be eligible for study, neither infants nor their mothers must not have previously been administered antibodies or a vaccine to prevent RSV or hMPV.
What we're hoping for
We are studying whether an mRNA vaccine is safe and effective in preventing respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections in babies 5< 8 months of age.
Additional Information
ClinicalTrials.gov Identifier: NCT05743881